0MH6.LSE Ipsen SA

Healthcare Commercial Services & Supplies London Exchange
- EUR
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
1.34%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2022.

Is 0MH6.LSE undervalued?

Graham number

The Graham number of Ipsen SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ipsen SA fundamental analysis

No fundamental analysis for Ipsen SA yet.

Ipsen SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ipsen SA

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, fema…

Full company profile